Duodenogastroesophageal reflux and biliary pathology


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The literary review highlights modern ideas about the problem of duodenogastroesophageal reflux (DGR) in biliary pathology, in particular in persons who have undergone cholecystectomy. The article presents current data on the contribution of DGR to the pathogenesis of gastroesophageal reflux disease, Barrett’s esophagus and esophageal adenocarcinoma. Features of mechanisms of direct damaging action and cytokine-mediated damage of upper gastrointestinal mucosa by bile acids in refluxate are described. Diagnostic methods for detection of DGR are discussed, particular attention is paid to the principles of treatment of patients with this condition.

Texto integral

Acesso é fechado

Sobre autores

Yu. Uspensky

St. Petersburg State Pediatric Medical University; Pavlov University

Email: uspenskiy65@mail.iu
St. Petersburg, Russia

Yu. Fominykh

St. Petersburg State Pediatric Medical University; Pavlov University

St. Petersburg, Russia

A. Gnutov

St. Petersburg State Pediatric Medical University

St. Petersburg, Russia

V. Filippova

St. Petersburg State Pediatric Medical University

St. Petersburg, Russia

Bibliografia

  1. Васнев О.С., Янова О Б. Симультанные операции у больных желчнокаменной и гастроэзофагеальной рефлюксной болезнью. Экспериментальная и клиническая гастроэнтерология. 2010;4:73-7
  2. Циммерман Я.С. Постхолецистэктомический син -дром, его сущность, клинические проявления, диагностика и лечение. Экспериментальная и клиническая гастроэнтерология 2017;144(8) 4-11
  3. Быстровская Е.В. Постхолецистэктомический синдром: патогенетические и терапевтические аспекты проблемы. Медицинский совет 2012;2:837
  4. McQuaid K.R., Laine L., Fennerty M.B., et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34:146-65. doi: 10.1111/j.1365-2036.2011.04709.x.
  5. Kuran S. Bile reflux index after therapeutic biliary procedures. BMC Gastroenterology 2008;8:4. doi: 10.1186/1471-230X-8-4.
  6. Mercan E., Duman U., Tihan D., Dilektasli E., Senol K. Cholecystectomy and duodenogastric reflux: interacting effects over the gastric mucosa. SpringerPlus. 2016;5:1970. doi: 10.1186/s40064-016-3641-z.
  7. Hyvarinen H. Relationship of previous cholecystectomy to oesophagitis and gastroduodenal ulcers. Hepatogastroenterology. 1987;34(2):74-80. PMID: 3596461.
  8. Jazrawi S., Walsh T.N., Byrne P.J., et al. Cholecystectomy and oesophageal reflux: a prospective evaluation. Br J Surg. 1993;80(1):50-3. doi: 10.1002/bjs.1800800119. PMID: 8428293.
  9. McNamara D.A., O'Donohoe M.K., Horgan PG., et al. Symptoms of oesophageal reflux are more commonfollowing laparoscopic cholecystectomy than in a control population. Ir J Med Sci. 1998;167(1):11- 3. doi: 10.1007/BF02937544. PMID: 9540290.
  10. Manifold D.K., Anggiansah A., Owen W.J. Effect of cholecystectomy on gastroesophageal and duodenogastric reflux. Am J Gastroenterol. 2000;95(10):2746-50. doi: 10.1111/j.1572-0241.2000.02298.x. PMID: 11051343.
  11. Kunsch S., et al. Increased Duodeno-Gastro-Esophageal Reflux (DGER) in Symptomatic GERD Patients with a History of Cholecystectomy. Z Gastroenterol. 2009;47:744-48.
  12. Lin O.S., Kozarek R.A., Arai A., et al. The association between cholecystectomy and gastroesophageal reflux symptoms: a prospective controlled study. Ann Surg. 2010;251(1):40-5. Doi: 10.1097/ SLA.0b013e3181b9eca4.
  13. Lagergren J., Mattsson F. Cholecystectomy as a risk factor for oesophageal adenocarcinoma. Br J Surg. 2011;98(8):1133-37. doi: 10.1002/bjs.7504. PMID: 21590760.
  14. Freedman J., Weimin Y.E., Naslund E., Lagergren J. Association Between Cholecystectomy and Adenocarcinoma of the Esophagus. Gastroenterology. 2001;121:548-53. doi: 10.1053/gast.2001.27217.
  15. Tack J. Review article: role of pepsin and bile in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;2(1):48-54. doi: 10.1111/j.1365-2036.2005.02609.x.
  16. Dixon M.F., Neville P.M., Mapstone N.P, et al. Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux? Gut. 2001;49:359-63. Doi: 10.1136/ gut.49.3.359.
  17. Kawabea A., et al. Production of prostaglandin E2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells. Life Sciences. 2004;75:21-34. doi: 10.1016/j.lfs.2003.11.022.
  18. Duggan S.P, et al. An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-kB activation and cytokine levels. Carcinogenesis. 2010;31(5):936-45. doi: 10.1093/carcin/bgq036.
  19. Zhang R, Gong J., Wang H., Wang L. Bile salts inhibit growth and induce apoptosis of cultured human normal esophageal mucosal epithelial cells. World J Gastroenterol. 2005;11(41):6466-71. doi: 10.3748/wjg.v11.i41.6466.
  20. Liu T, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007;28(2):488-96. Doi: 10.1093/ carcin/bgl176.
  21. Morrow D.J., et al. Pathogenesis of Barrett's esophagus: Bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery. 2009;146(4):714-22. Doi: 10.1016/ j.surg.2009.06.050.
  22. Debruyne P.R, Witek M., Gong L., et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology. 2006;130(4): 1191 -206. Doi: 10.1053/j. gastro.2005.12.032. PMID: 16618413.
  23. Hashimoto N. Cholecystectomy and Duodenogastric Reflux-: Reflux of Duodenal Content Induces Esophageal Carcinogenesis. Clin Surg. 2018;3:1867.
  24. Sun D., et al. Bile acids but not acidic acids induce Barrett's esophagus. Int J Clin Exp Pathol. 2015;8(2):1384-92.
  25. Nehra D, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44:598-602. doi: 10.1136/gut.44.5.598.
  26. Perng D.W, Chang K.T, Su K.C., et al. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation. Chest. 2007;132(5):1548-56. Doi: 10.1378/ chest.07-1373.
  27. Eldredge T.A., Myers J.C., Kiroff G.K., Shenfine J. Detecting Bile Reflux - the Enigma of Bariatric Surgery. Obesity Surgery. 2018;28:559-66. doi: 10.1007/s11695-017-3026-6.
  28. Peng S., et al. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307:129-39. Doi: 10.1152/ ajpgi.00085.2014.
  29. Souza R.F. From Reflux Esophagitis to Esophageal Adenocarcinoma. Dig Dis. 2016;34(5):483-90. doi: 10.1159/000445225. PMID: 27331918.
  30. Wu Y.C., Chiu C.F, Hsueh C.T., Hsueh C.T. The role of bile acids in cellular invasiveness of gastric cancer. Cancer Cell Int. 2018;18:75. Doi: 10.1186/ s12935-018-0569-0.
  31. Lim S.C., Han S.I. Ursodeoxycholic acid effectively kills drug-resistant gastric cancer cells through induction of autophagic death. Oncol Rep. 2015;34(3):1261-68. doi: 10.3892/ or.2015.4076. PMID: 26133914.
  32. Цуканов В.В., Онучина Е.В., Каспаров Э.В. и др. Опыт длительной терапии пациентов с пищеводом Барретта. Фарматека. 2015;2:62-5.
  33. Leman D.A., Riff B.P, Morgan S., et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1-9. doi: 10.1093/dote/dow020.
  34. Минушкин О.Н. Место альгинатов в лечении кислотозависимой гастроэзофагеальной рефлюксной болезни. Лечащий врач. 2015;11:4.
  35. Бордин Д.С. «Кислотный карман» как п атогенетическая основа и терапевтическая мишень при гастроэзофагальной рефлюксной болезни. Терапевтический архив. 2014;2:76-81.
  36. Мартынов А.И., Шептулин А.А., Маев И.В. и др. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):7-14.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies